

For anemia associated with chronic kidney disease



**Aranesp® should be dosed less frequently than Epoetin alfa<sup>1</sup>**

Converting from Epoetin alfa TIW to Aranesp® QW

| Previous Weekly Epoetin alfa Dose (units/week) | Weekly Aranesp® Dose (mcg/week) |
|--|---------------------------------|
| 11,000 to 17,999                               | 40                              |
| 18,000 to 33,999                               | 60                              |
| 34,000 to 89,999                               | 100                             |
| ≥ 90,000                                       | 200                             |

**Example:** If you currently administer 3,500 units of Epoetin alfa TIW (10,500 units per week), give 25 mcg of Aranesp® QW.

- Determine the total 1-week dose of Epoetin alfa.
- Refer to the above chart to determine the appropriate starting Aranesp® QW dose.
- Available in six convenient Aranesp® SingleJect® prefilled syringe and vial strengths: 25 mcg, 40 mcg, 60 mcg, 100 mcg, 150 mcg, and 200 mcg.

Aranesp® is indicated for the treatment of anemia associated with chronic renal failure (CRF), including patients either on or not on dialysis.

Recommended starting dose for new patients is 0.45 mcg/kg/wk (SC or IV). Aranesp® should be administered QW if a patient was receiving Epoetin alfa BIW or TIW. Please refer to the Dosage and Administration section of the Aranesp® package insert for complete conversion information.

Please also refer to the accompanying Aranesp® package insert for full prescribing information.

1. Aranesp® (darbepoetin alfa) prescribing information, Amgen.



Amgen  
The Amgen Family  
Biotech® Public Company  
www.amgen.com



**Aranesp®**  
(darbepoetin alfa)

For anemia associated with chronic kidney disease



**Aranesp® should be dosed less frequently than Epoetin alfa<sup>1</sup>**

Converting from Epoetin alfa QW to Aranesp® Q2W

| Cumulative 2-Week Epoetin alfa QW Dose (units) | Q2W Aranesp® Dose (mcg) |
|--|-------------------------|
| 5,000 to 10,999                                | 25                      |
| 11,000 to 17,999                               | 40                      |
| 18,000 to 33,999                               | 60                      |
| 34,000 to 89,999                               | 100                     |
| ≥ 90,000                                       | 200                     |

**Example:** If you currently administer 10,000 units of Epoetin alfa QW, you would double this amount (20,000 units) to determine the appropriate Aranesp® Q2W dose. In this example, 60 mcg of Aranesp® would be given Q2W.

- Determine the weekly dose of Epoetin alfa and multiply by 2.
- Refer to the above chart to determine the appropriate starting Aranesp® Q2W dose.
- Titrate as necessary to maintain a target hemoglobin (Hb) not to exceed 12 g/dL.

Aranesp® is contraindicated in patients with uncontrolled hypertension. Increases in hemoglobin greater than approximately 1.0 g/dL during any 2-week period have been associated with serious side effects. The most commonly reported side effects in Aranesp® trials were infection, hypertension, hypotension, myalgia, headache, and diarrhea.

Amgen's Medical Information Connection™ is available to answer medical, clinical, or other questions regarding Amgen products.

Call or visit us on the Web:  
**1-800-77-AMGEN (1-800-772-6436)**  
(Monday through Friday,  
10 AM to 7 PM ET)

www.amgenmedinfo.com  
www.aranesp.com



**Aranesp®**  
(darbepoetin alfa)

© 2004, Amgen. All rights reserved. M123599 33M06-04 P55161